$1.52 Billion is the total value of Novo Holdings A/S's 47 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 15.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | LANZATECH GLOBAL INC | $61,361,599 | – | 15,814,845 | +100.0% | 4.05% | – | |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $35,724,031 | +8.7% | 367,380 | +15.6% | 2.36% | +14.8% |
| VECT | Buy | VECTIVBIO HLDG AG | $30,725,023 | +6.2% | 3,610,461 | +8.1% | 2.03% | +12.2% |
| PCVX | Buy | VAXCYTE INC | $27,922,600 | -19.7% | 745,000 | +2.8% | 1.84% | -15.1% |
| ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $23,714,483 | -10.9% | 118,383 | +5.7% | 1.56% | -5.8% |
| INSM | Buy | INSMED INC | $22,835,133 | +36.1% | 1,339,304 | +59.4% | 1.51% | +43.8% |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $20,191,692 | +24.6% | 448,804 | +21.3% | 1.33% | +31.6% |
| CRNX | Buy | CRINETICS PHARMACEUTICALS IN | $17,666,000 | +31.0% | 1,100,000 | +49.2% | 1.17% | +38.5% |
| VERV | Buy | VERVE THERAPEUTICS INC | $17,304,000 | -1.8% | 1,200,000 | +31.7% | 1.14% | +3.7% |
| Buy | DICE THERAPEUTICS, INC. | $16,726,320 | +15.3% | 536,100 | +15.3% | 1.10% | +21.9% | |
| RCKT | Buy | ROCKET PHARMACEUTICALS INC | $15,759,600 | -5.3% | 920,000 | +8.2% | 1.04% | +0.1% |
| BLU | Buy | BELLUS HEALTH INC. | $15,393,420 | +10.3% | 2,137,975 | +25.9% | 1.02% | +16.6% |
| SPRB | Buy | SPRUCE BIOSCIENCES INC | $14,856,363 | +200.0% | 6,722,336 | +48.9% | 0.98% | +217.2% |
| FDMT | New | 4D MOLECULAR THERAPEUTICS IN | $12,033,000 | – | 700,000 | +100.0% | 0.79% | – |
| PHVS | Buy | PHARVARIS N V | $10,714,360 | -19.8% | 1,329,325 | +12.0% | 0.71% | -15.2% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VANGUARD INDEX FDS | 41 | Q3 2022 | 64.7% |
| INOGEN INC | 34 | Q2 2022 | 68.8% |
| VANGUARD INTL EQUITY INDEX F | 29 | Q4 2016 | 37.6% |
| AMICUS THERAPEUTICS INC | 22 | Q3 2023 | 4.1% |
| AKEBIA THERAPEUTICS INC | 21 | Q3 2020 | 4.8% |
| VERONA PHARMA PLC | 21 | Q2 2022 | 1.9% |
| CORVUS PHARMACEUTICALS INC | 20 | Q4 2020 | 7.1% |
| INSPIRE MED SYS INC | 20 | Q3 2023 | 1.8% |
| CABLE ONE INC | 19 | Q3 2023 | 9.7% |
| FLEXION THERAPEUTICS INC | 19 | Q3 2021 | 4.7% |
View Novo Holdings A/S's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyteir Therapeutics, Inc. | August 03, 2023 | 1,547,136 | 4.4% |
| Disc Medicine, Inc. | June 28, 2023 | 1,090,772 | 4.8% |
| Galera Therapeutics, Inc. | June 28, 2023 | 2,100,000 | 4.9% |
| VectivBio Holding AGSold out | May 26, 2023 | 0 | 0.0% |
| LanzaTech Global, Inc. | February 17, 2023 | 15,814,845 | 8.1% |
| Bolt Biotherapeutics, Inc.Sold out | January 04, 2023 | 0 | 0.0% |
| Arcellx, Inc. | December 12, 2022 | 1,750,000 | 4.0% |
| MINERVA SURGICAL INC | November 03, 2022 | 1,322,473 | 4.5% |
| Milestone Pharmaceuticals Inc. | October 24, 2022 | 1,378,538 | 4.6% |
| Galecto, Inc. | September 30, 2022 | 2,497,791 | 9.8% |
View Novo Holdings A/S's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-03-28 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 144 | 2024-03-18 |
| 4 | 2024-03-18 |
| SC 13D/A | 2024-03-18 |
| 144 | 2024-03-14 |
| SC 13D/A | 2024-03-07 |
View Novo Holdings A/S's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.